皮肤黑色素瘤的临床特征与预后
该研究回顾性分析125例皮肤黑色素瘤患者的临床与随访资料,采用Kaplan-Meier法和Cox回归分析预后。全组中位总生存44个月,1、2、5年生存率分别为85.4%、63.2%和38.7%;肿瘤分期及术前LDH水平为独立预后危险因素。
要点
- 全组125例皮肤黑色素瘤患者中位总生存44个月,1、2、5年生存率分别为85.4%、63.2%和38.7%。
- Ⅲ期患者接受干扰素治疗中位OS 40个月,优于未接受者的17个月(P=0.012)。
- Ⅱ期肢端型预后优于非肢端型(P=0.043);肿瘤分期及术前LDH为独立危险因素。
核心结论
- 干扰素治疗可以改善Ⅲ期患者预后;Ⅱ期肢端型患者预后优于非肢端型患者;肿瘤分期及术前LDH水平为皮肤黑色素瘤患者预后的独立危险因素。
研究设计与样本
- 收集2008年2月至2019年8月于华中科技大学同济医学院附属同济医院治疗的125例皮肤黑色素瘤患者的临床病理资料。
- 生存分析采用Kaplan-Meier法和Log rank检验,影响因素分析采用Cox比例风险回归模型。
主要发现
- 125例患者中Ⅰ期12例、Ⅱ期62例、Ⅲ期30例、Ⅳ期21例;肢端型76例、非肢端型49例。
- 全组中位总生存时间44个月,1、2、5年生存率分别为85.4%、63.2%和38.7%。
- Kaplan-Meier单因素分析显示卡氏体力状态评分、肿瘤分期、原发灶部位、脉管浸润、Ki-67指数、BRAF基因、术前LDH水平、手术治疗与预后有关(均P<0.05)。
- 接受干扰素治疗患者中位OS 53个月 vs 未接受干扰素治疗患者40个月,差异无统计学意义(P=0.448);Ⅲ期患者中接受干扰素治疗中位OS 40个月 vs 未接受者17个月(P=0.012)。
- Ⅱ期肢端型1、2、5年生存率分别为97.1%、84.7%、65.8%,非肢端型分别为93.3%、70.0%、17.0%(P=0.043);Ⅲ期肢端型中位OS 32个月 vs 非肢端型17个月(P=0.164);Ⅳ期肢端型中位OS 8个月 vs 非肢端型11个月(P=0.458)。
关键数值与推荐
- Cox多因素分析显示肿瘤分期及术前LDH水平为皮肤黑色素瘤患者预后的独立危险因素(均P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical features and prognosis of patients with cutaneous melanoma. Methods: The clinical data and follow-up data of 125 patients with cutaneous malignant melanoma (CMM) treated in the Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology between February 2008 and August 2019 were collected. Kaplan-Meier method and Log rank test were used for survival analysis, and Cox proportional risk regression model was used for impact factor analysis. Results: Among the 125 patients, 12 were stage Ⅰ, 62 were stage Ⅱ, 30 were stage Ⅲ, and 21 were stage Ⅳ; 76 were acral and 49 were non-acral. The median survival time was 44 months, and the 1-, 2-, and 5-year survival rates were 85.4%, 63.2% and 38.7%, respectively. Kaplan-Meier univariate survival analysis showed that Karnofsky performance status score, tumor stage, primary site, vascular infiltration, Ki-67, BRAF, lactate dehydrogenase (LDH), and surgical treatment were related to the prognosis of patients (P<0.05). The median overall survival (OS) time of patients receiving interferon treatment was 53 months, which was better than 40 months of patients not receiving interferon treatment, but the difference was not statistically significant (P=0.448). Among stage Ⅲ patients, the median OS time of patients receiving interferon therapy was 40 months, which was better than 17 months of patients not receiving interferon therapy (P=0.012). Among stage Ⅱ patients, the 1-, 2-, and 5-year survival rates of acral patients were 97.1%, 84.7%, and 65.8%, and the 1-, 2-, and 5-year survival rates of non-acral patients were 93.3%, 70.0% and 17.0%. The prognosis of patients with stage Ⅱ acral type was better than that of non-acral type (P=0.043). The median survival time of stage Ⅲ patients with acral type was 32 months, better than 17 months of non-acral type, but the difference was not statistical significance (P=0.164). The median survival time of acral type and non-acral type was 8 months and 11 months respectively (P=0.458). Cox multivariate analysis showed that tumor stage and preoperative LDH level were independent prognostic risk factors for cutaneous melanoma. Conclusions: Interferon treatment can improve the prognosis of patients with stage Ⅲ, and stage Ⅱ acral type patients have better prognosis than that of non-acral type patients. Tumor stage and preoperative LDH level were independent prognostic risk factors for cutaneous melanoma. 目的:探讨皮肤黑色素瘤患者的临床病理特征及预后。 方法:收集2008年2月至2019年8月于华中科技大学同济医学院附属同济医院治疗的皮肤黑色素瘤患者的临床病理资料,生存分析采用Kaplan-Meier法和Log rank检验,影响因素分析采用Cox比例风险回归模型。 结果: 125例患者中,Ⅰ期12例,Ⅱ期62例,Ⅲ期30例,Ⅳ期21例;肢端型76例,非肢端型49例。全组患者中位总生存时间(OS)为44个月,1、2、5年生存率分别为85.4%、63.2%和38.7%。卡氏体力状态评分、肿瘤分期、原发灶部位、脉管浸润、ki-67指数、BRAF基因、术前乳酸脱氢酶(LDH)水平、手术治疗与患者预后有关(均P<0.05)。接受干扰素治疗患者的中位OS(53个月)优于未接受干扰素治疗的患者(40个月,P=0.448);Ⅲ期患者中,接受干扰素治疗患者的中位OS(40个月)优于未接受干扰素治疗的患者(17个月,P=0.012)。Ⅱ期患者中,肢端型患者1、2、5年生存率分别为97.1%、84.7%和65.8%,非肢端型患者1、2、5年生存率分别为93.3%、70.0%和17.0%;Ⅱ期肢端型患者预后优于非肢端型患者(P=0.043)。Ⅲ期患者肢端型中位OS(32个月)优于非肢端型患者(17个月,P=0.164)。Ⅳ期患者肢端型中位OS(8个月)短于非肢端型患者(11个月,P=0.458)。肿瘤分期及术前LDH水平为皮肤黑色素瘤患者预后的独立危险因素(均P<0.05)。 结论:干扰素治疗可以改善Ⅲ期患者预后,Ⅱ期肢端型患者预后优于非肢端型患者,肿瘤分期及术前LDH水平为皮肤黑色素瘤患者预后的独立危险因素。.
引用
- Tian Y, Li MW, Liu QK, et al. [Clinical features and prognosis of cutaneous melanoma]. Zhonghua Zhong Liu Za Zhi. 2022. PMID: 36319462. doi:10.3760/cma.j.cn112152-20200818-00751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。